

Seppic injectable polysorbates Montanox™ 80 PPI and Montanox™ 20 PPI are now compliant in the Chinese market

Montanox™ 80 PPI et Montanox™ 20 PPI, ingredients developed and produced by Seppic, comply with the current Chinese pharmacopoeia and will be marketed in China from May 2021.

As a supplier of specialty **healthcare ingredients**, Seppic is active in the **parenteral excipients** market with various solutions including its Montanox™ range of polysorbates acting as solubilizers or stabilizers.

The parenteral excipients market is growing at a rate of 10% per year, due to the increasing number of biologics requiring parenteral administration and the increasing number of active ingredients with low solubility, requiring a solubilizer to achieve an effective formulation.

The **Montanox™ injectable** range is used to solubilize pharmaceutical and/or biological active ingredients and to formulate oil-in-water emulsions.

Montanox™ 80 PPI and Montanox™ 20 PPI are the result of Seppic's expertise in manufacturing high purity excipients that meet the highest European Good Manufacturing Practice ("EU GMP part II") standards. With its excipients, Seppic offers the highest level of safety and reliability to its customers worldwide.

Célia Hérou, Market Manager for Pharmaceuticals at Seppic, states : *"By being compliant to this Chinese Pharmacopoeia, we are meeting the increased regulatory requirements and demands of the global pharmaceutical market. Seppic's strength is that we control all stages of product manufacturing, following GMP"*

Seppic in brief

A company of Air Liquide Healthcare, Seppic has been designing, producing and distributing for more than 75 years a wide range of **specialty ingredients for health and beauty**. Present in **100 countries** through its subsidiaries and its network of distributors, Seppic employs more than **800 people** worldwide, including **110 employees dedicated to innovation**. www.seppic.com

Air Liquide Healthcare

Supplies **medical gases, home healthcare services, medical equipment and specialty ingredients**.

In 2020, it served over **15,000 hospitals and clinics** and more than **1.8 million patients** at home throughout the world. The Group's Healthcare business reached **€3,724 million in revenues in 2020**, with the support of its **15,600 employees**.



CONTACTS

Seppic Communications

Alexandra Gilbert
+33 (0)1 42 91 41 18

FP2COM for Seppic

Florence Portejoie
+ 33 (0) 6 07 76 82 83

A world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 67,000 employees and serves more than 3.7 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the company's activities since its creation in 1902.

Air Liquide's ambition is to be a leader in its industry, deliver long term performance and contribute to sustainability. The company's customer-centric transformation strategy aims at profitable, regular and responsible growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.

Air Liquide's revenue amounted to 22 billion euros in 2020 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.